ABSTRACT
The efficacy and tolerability of the combined scheme of administering high dose medroxyprogesterone acetate in advanced breast cancer is evaluated.
Subject(s)
Administration, Oral , Aged , Antineoplastic Agents/administration & dosage , Breast Neoplasms/drug therapy , Female , Humans , Injections, Intramuscular , Medroxyprogesterone/administration & dosage , Medroxyprogesterone Acetate , Middle AgedABSTRACT
Twenty eight patients (22 males, 6 females), with mean age of 55 years (range 34-71 years) were given combination chemotherapy consisting of Cis-platinum and VP 16-213 (Etoposide). The schedule was Cis-platinum, 20 mg/m2 and VP 16-213, 60 mg/m2, each given for 5 consecutive days and repeated every 4 weeks. Histological subgroups were adenocarcinoma 15, squamous cell carcinoma 9 and large cell carcinoma 4. Prior therapy was radiotherapy in 2 and no treatment in 15 patients. The ECOG performance status was 0-1 in 9 patients and 2-3 in 9 patients. Eight patients had limited disease and 20 had extensive disease. Nine of 28 patients responded, 1 CR and 8 PR's, with an overall response rate of 32%. The median duration of response was 23 weeks. Response rates according to histologic types were similar. Important prognostic factors for response were performance status, stage of the diseases and age below 55 years. Median survival was significantly longer for patients with limited disease vs extensive disease (41 vs 22.5 weeks) and in responders vs non-responders (42 vs 22 weeks). Toxicity was tolerable. This regimen is recommended for subsets of patients with the above prognostic factors.
Subject(s)
Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Bone Marrow/drug effects , Cisplatin/administration & dosage , Etoposide/administration & dosage , Female , Humans , Lung Neoplasms/drug therapy , Male , Middle AgedABSTRACT
Twenty-two patients with advanced or recurrent cancer of the cervix treated with cis-platinum, adriamycin and cyclophosphamide were evaluated. Nine of 22 (41% achieved objective response (2 CR + 7PR), 9/22 (41%) stable disease, 4/22 (18%) progressive disease. The mean duration of response was 24.6 weeks, with a range of 18-28 weeks. Patients with poorly differentiated histologic grade and without previous treatment had better response rates. Responders had longer survival (mean 63.5 + weeks) than nonresponders (mean 30.5 weeks). Commonly encountered toxicities were alopecia, nausea and vomiting, and leucopenia, which were all tolerable.